¹**Immunosenescence profile is associated with increased susceptibility to severe** ²**COVID-19**

3 Lucas Haniel A. Ventura^{1#}, Lícia Torres^{1#}, Giovanna Caliman Camatta¹, Jofer
4 Zamame², Monique Macedo Coelho¹, Cecília Horta Ramalho-Pinto¹, João Gervazio¹, zamame², Monique Macedo Coelho¹, Cecília Horta Ramalho-Pinto¹, João Gervazio¹, 5 Felipe Caixeta¹, Leandro Nascimento¹, Mariana Almeida Oliveira¹, Vinícius Dantas 6 Martins¹, Marcos Felipe Oliveira¹, Murilo Soares da Costa³, Hugo Itaru Sato¹, Henrique
Carqueire Guimerães⁴, Befeel, Gelvãe, Berbute⁴, Are, Peule, Beebe, Veice⁵, Neigre 7 Cerqueira Guimarães⁴, Rafael Calvão Barbuto⁴, Ana Paula Rocha Veiga⁵, Najara
2. Ataída⁵ Cabriela Prandi Castano⁵, Samb Bangan⁵ Maure Lúcie O Júnice⁶ Fernanda 8 Ataíde⁵, Gabriela Prandi Caetano⁵, Sarah Rangon⁵, Mauro Lúcio O. Júnior⁶, Fernanda
Colato Fertas¹, Luciana Zusebarata¹, Eleina Spariali^{7,8}, Olinda Assis Martina Filha⁷ Successive Calvo Fortes¹, Luciana Zuccherato¹, Elaine Speziali^{7,8}, Olindo Assis Martins-Filho⁷, Nortes Coolho⁹, Peberte Avritabiu¹⁰, Refeel Sourc⁵, Martine Avrita², Colo I outning² 10 Verônica Coelho⁹, Roberto Avritchir¹⁰, Rafael Souza⁵, Marina Ayupe², Caio Loureiro²,
11 Marie Eduarda Peasas¹¹, Ara, Clara Mata Nausa¹¹, Paulina Leita¹¹, Sontura Maria. 11 Maria Eduarda Passos¹¹, Ana Clara Mota Neves¹¹, Pauline Leite¹¹, Santuza Maria
12 Ribeiro Teixeira¹, Unaí Tupinambas³, Liza Figueiredo Felicori¹, Gabriela Silveira-12 Ribeiro Teixeira¹, Unaí Tupinambas³, Liza Figueiredo Felicori¹, Gabriela Silveira-
13 Munea¹¹ Tetieni Heali Meieli^{1,12} Denice Mergie Feneces², Andrea Teixeira Carvelhe⁷ 13 Nunes¹¹, Tatiani Uceli Maioli^{1,12}, Denise Morais Fonseca², Andrea Teixeira-Carvalho⁷,
14, Ane Merie Gestane Ferie^{1*} 14 Ana Maria Caetano Faria^{1*}

- ¹ Departamento de Bioquímica e Imunologia, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil 17 Minas Gerais, Belo Horizonte, Brazil
- ² Departamento de Imunologia, Instituto de Ciências Biomédicas, Universidade de São Paulo, Brazil
- ³ Departamento de Doenças Tropicais e Infecciosas, Faculdade de Medicina, Universidade Federal de Medicinas Gerais Belo Horizonte Brazil ²⁰Minas Gerais, Belo Horizonte, Brazil
- ⁴ Hospital Risoleta Tolentino Neves, Belo Horizonte, Brazil.
- ⁵ Instituto de Infectologia do Hospital Emílio Ribas, São Paulo, Brazil.
- ⁶ Hospital da UNIMED, Governador Valadares, Brazil
- 24 $\frac{7}{1}$ Instituto de Pesquisa René Rachou, Fundação Oswaldo Cruz, Belo Horizonte, Brazil
- ⁸ Universidade Edson Antônio Velano, Fundação de Ensino e Tecnologia de Alfenas, Belo Horizonte,
26 Prazil 26 Brazil.
- ⁹ Instituto do Coração, Universidade de São Paulo, São Paulo, Brazil.
- 28 ¹⁰ Santa Casa de Misericórdia, São Paulo, Brazil.
- ¹¹ Departamento de Medicina, Universidade Federal de Juiz de Fora, Governador Valadares, Brazil
- ¹² Departamento de Nutrição, Escola de Enfermagem, Universidade Federal de Minas Gerais, Belo
31 de Horizonte Brazil 31 Horizonte, Brazil
-
- 33 # These authors contributed equally to this study.
34 * Corresponding Author: Ana Maria Caetanc

³⁴***Corresponding Author:** Ana Maria Caetano Faria, Departamento de Bioquímica e Imunologia, 35 Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Antônio Carlos, 6627, Belo
36 Horizonte, CEP 31270-901, MG, Brazil. E-mail: anacaetanofaria@gmail.com Horizonte, CEP 31270-901, MG, Brazil. E-mail: anacaetanofaria@gmail.com

- 37
- ³⁸**Key words:** Immunosenescence, Inflammaging, COVID-19, Immunoglobulin repertoire, T cell senescence, T cell exhaustion, epigenetic clock
-

⁴¹**Abstract:**

⁴²In this study we tested the hypothesis that the immunosenescence profile could account 43 for the disproportional susceptibility of the elderly to severe forms of COVID-19. The 44 immunological profiles of volunteers residing in endemic and non-endemic areas for
45 chronic infectious diseases were analyzed at early stage of SARS-CoV-2 infection. A chronic infectious diseases were analyzed at early stage of SARS-CoV-2 infection. A ⁴⁶unique signature of inflammatory plasma mediators was identified in COVID-19 47 volunteers when compared to individuals with other flu-like syndromes. COVID-19 48 severity correlated with high levels of inflammatory mediators; among them, CXCL9, a ⁴⁹serum marker of aging. Patients who progressed to hospitalization displayed high 50 frequencies of $CD8^+$ and $CD4^+$ T cells expressing exhaustion and senescence markers 51 and showed reduced and more mature B cell repertoires, which are typical of 52 senescence. They also had an acceleration of epigenetic age measured by DNA 53 methylation. Therefore, severe COVID-19 correlated with phenotypic, functional, and 54 epigenetic features of accelerated immunosenescence at onset of infection.

⁵⁵**Introduction:**

57 Since the onset of COVID-19 cases, the elderly have been the main risk group 58 for severe disease worldwide. This pattern of susceptibility was reported initially in 59 China¹, Italy² and later in several countries including Brazil³.

⁶⁰SARS-CoV-2 infection is cleared by a normal anti-viral response in most 61 individuals, but some progress to a hyperinflammatory condition, often with severe 62 pulmonary involvement. It has been shown that $5-6\%$ of these patients need mechanical 63 ventilation due to respiratory failure developed by lung and microcirculation damage, ⁶⁴with profound hypoxia, severe acute respiratory syndrome (SARS) and multiple organ ⁶⁵dysfunction. These individuals have systemic hyperinflammation with classical serum 66 biomarkers of "cytokine storm syndrome" including abnormal coagulation, elevated C 67 reactive protein (CRP), LDH, ferritin, IL-1β, TNF, IL-6, IFN-γ, IL-10, IL-15, IL-2, IL-5, CCL2, CCL3, CCL4 and CXCL10⁴. Therefore, uncontrolled inflammation is clearly 69 associated with severe life-threatening COVID-19. Interestingly, many of these ⁷⁰mediators are the ones found to induce a low-grade chronic state of inflammation 71 known as inflammaging and originated from senescent cells, cumulative stimulation of 72 immune cells and lifestyle risk factors 5.6 .

⁷³Aging affects all body compartments, but the immune system is particularly ⁷⁴impacted. Immunosenescence is associated with a decline in the production and activity ⁷⁵of T and B cells, many defects in innate immune cells, and thymic atrophy. The 76 progressive reduction in the output of naïve T cells from the thymus creates an 77 oligoclonal repertoire of expanded subsets of memory T cells and exhausted/senescent ⁷⁸lymphocytes (mostly CD8 T cells) with low proliferative capacity. At the same time, ⁷⁹senescent immune and non-immune cells develop a secretory phenotype (SASP) that 80 includes innate cytokines and chemokines such as CXCL8, IL-6, IL-18, TNF and IL-1 β 81 responsible for the development of the inflammaging⁶. Immunosenescence is also 82 associated with a reduction in production of B cells by the bone marrow. This decline in ⁸³T/B cell production leads to the peripheral accumulation of cells with an exhausted 84 repertoire displaying lower diversity of T/B cell receptors 7,8 , and poor responses to 85 infectious agents and vaccines $6,9,10$. Thus, response to a virus infection such as SARS-86 CoV-2 in the elderly can be very abnormal as already observed for other viruses $\frac{11}{16}$.

87 Interestingly, not all elderly developed the severe form of COVID-19^{12} and not 88 all aged individuals have a dysfunctional immunological profile. Studies on healthy 89 nonagenarians and centenarians in Italy and on healthy elderly people in Brazil showed 90 that these individuals develop remodelling mechanisms to control the deleterious effects 91 of inflammation and immunosenescence $6,13-15$. On the other hand, our group have ⁹²shown that individuals living in endemic areas for infectious diseases (such as ⁹³Schistosomiasis, Leishmaniasis, Leprosy, Chagas Disease, Dengue, Chikungunya, 94 Yellow Fever) exhibit an accelerated biological age as measured by DNA methylation¹⁶ 95 with an unique immunological profile^{14,17-20}. Therefore, aging does not affect ⁹⁶individuals homogeneously and the resulting senescence phenotype seems to be 97 determined by genetic, epigenetic and biographical factors related to the interactions of 98 the immune system and the body with its environment.

99 Our hypothesis in this study is that the immunosenescence profile, rather than 100 the chronological age, will impact on the development of the inflammatory damage seen 101 in severe COVID-19 by creating a permissive environment for a dysfunctional response 102 to the virus. Moreover, it is likely that factors such as chronic antigenic exposure in 103 endemic areas for infectious diseases would enhance a preexisting immunosenescence 104 phenotype.

105 Although some authors have theoretically proposed an association between ¹⁰⁶COVID-19 severity and senescence biomarkers such as inflammaging, biological 107 clocks, mTOR activity, and telomer shortening $21-24$, only few studies have ¹⁰⁸experimentally addressed this proposal using only cohorts of hospitalized individuals at 109 heterogeneous time points of infection with mixed results $25,26$.

110 Several distinctive parameters were used in this study to reach non-ambiguous 111 conclusions when testing our hypothesis: (i) we investigated individuals from three 112 cities in Brazil with distinct patterns of biological aging; (ii) our cohort had only ¹¹³individuals at early stage of infection (1-4 days of symptoms) to avoid confusion 114 between the impact of immunosenescence in COVID-19 outcome with accelerated 115 immunosenescence induced by SARS-CoV-2 infection itself 27 ; (iii) a group of 116 individuals with flu-like symptoms but negative for SARS-CoV-2 infection was 117 included as a control to distinguish COVID-19 from other airway viral infections; (iv) 118 all individuals were clinically followed for 14 days to monitor disease progression, 119 sometimes from mild to severe, as in the case of a specific group of patients

¹²⁰(progression group); (v) four parameters were tested to make up the immunosenescence 121 profile - plasma mediators to examine the inflammaging, phenotypical biomarkers of ¹²²memory, exhaustion and senescence in T cells, diversity and maturity of B cell 123 repertoires and the epigenetic age of the individuals.

¹²⁵**Results**

126

¹²⁷**Severe COVID-19 associated with a high inflammatory profile at early stage of** infection.

¹²⁹The main features of our study population are shown in **Table 1** and **2**. For all 130 the analysis reported below, individuals in each group were matched by age, sex and 131 number of comorbidities. We only included in the analysis individuals at early stage of 132 infection (1-4 days of symptoms). Other factors that could interfere with the 133 interpretation of our data were also controlled. (i) There was no significant difference in 134 the body mass index (BMI) among the groups that could contribute as an inflammatory 135 stimulus to the distinct outcomes 28 . (ii) The presence of comorbidities was a general 136 feature of our cohort, and the most reported ones were hypertension, diabetes mellitus, 137 and respiratory diseases. Since they are inflammatory conditions that could interfere 138 with COVID-19 severity 29 , all groups analysed in this study were matched by the 139 presence of an equal number of comorbidities (considered as equivalent conditions). ¹⁴⁰(iii) To exclude the possibility that disease outcome would be related to differences in 141 viral load as already reported for other infections by virus such as influenza 30 and 142 adenovirus 31 , concentration values for SARS-CoV-2 ribonucleic acid in each swab ¹⁴³sample were calculate and compared among clinical groups. We used cycle threshold ¹⁴⁴(Ct) values as a surrogate for viral load given the already reported linear correlation 145 between Ct values and viral concentration down to the limit of detection³². ¹⁴⁶**Supplementary Figure 1a** shows that individuals with mild, moderate, and severe ¹⁴⁷COVID-19 presented comparable CT values indicating that disease outcome was not 148 due to the abundance of virus in the respiratory tract. (iv) Individuals previously 149 infected by SARS-CoV-2 were identified by serology (using Bio-Plex Multiplex SARS-¹⁵⁰CoV-2 Serology Assay Kit) and excluded from the study. (v) Since a high prevalence of 151 Vitamin D deficiency has been reported to correlate with increased morbidity and 152 mortality related to COVID-19 infection 33 , serum levels of vitamin D were measured in

¹⁵³individuals of our cohort. No significant difference among the clinical groups of ¹⁵⁴COVID-19 was observed (**Supplementary Figure 1b**) ruling out the possible influence 155 of its deficiency in the outcome of the disease.

156 Since previous studies have shown that inflammaging is a hallmark of 157 immunosenescence¹⁰, we first characterized the inflammatory profile of the individuals ¹⁵⁸in all groups using a Luminex-Multiplex assay for 27 immune mediators. For this first 159 analysis, the study population was segregated into five groups: Flu-like Syndrome ¹⁶⁰(FLS) group comprising individuals who were negative for SARS-CoV-2 and had an 161 unknown mild respiratory infection, Mild, Moderate and Severe COVID-19 groups 162 according to WHO classification guidelines³⁴ (**Supplementary Table 1**). The fifth 163 group (Progression) consisted of individuals who were classified as Mild COVID-19 at 164 recruitment but progressed to severe disease with hospitalization during the 14-day 165 follow-up period.

166 A radar chart showing a global analysis of plasma mediators produced by 167 individuals with mild, moderate, and severe COVID-19 shows that, at early stage of ¹⁶⁸infection, disease severity was already positively correlated with the frequency of high 169 producers of several inflammatory mediators (**Figure 1a**). Among these mediators, we 170 identified 10 that were significantly different among the groups (**Figure 1b**): CCL2, ¹⁷¹CXCL8, CXCL10, IL-1β, IL-6, TNF, IFN-gamma, IL-12p70, IL-1Ra, IL-10. These are 172 classical inflammatory mediators that are part of the inflammaging phenotype $10,35$ and 173 were already reported to be at high levels in hospitalized COVID-19 patients. ¹⁷⁴Interestingly, the same list of mediators was also significantly higher in individuals with 175 mild COVID-19 when compared to the ones with flu-like syndrome (**Figure 1b**). ¹⁷⁶Although individuals from these two groups shared a spectrum of symptoms and could 177 only be segregated after RT-PCR testing for SARS-CoV-2 infection, they had a distinct 178 inflammatory profile. Mild COVID-19 patients presented a higher global pattern of ¹⁷⁹mediator production (**Figure 1c**) and several differences in the concentrations of the 10 ¹⁸⁰mediators (**Figure 1d, Supplementary Figure 2c**) since early infection. We also 181 observed differences in this inflammatory profile at other time points of disease 182 progression with higher immune activation in mild COVID-19 patients when compared ¹⁸³to FLS patients with 5-9 and 10-14 days of symptoms (**Supplementary Figure 2 d, e**). ¹⁸⁴Probably at this stage, immune mediators resulting from the response to infection are at 185 play. Therefore, COVID-19 seems to be related to a unique inflammatory profile when

186 compared to other respiratory viral infections with similar symptoms. Notably, when 187 patients with mild COVID-19 were segregated into adults and elderly, a higher global 188 profile of inflammatory immune activation was detected in aged individuals ¹⁸⁹(**Supplementary Figure 2b, e**) during early stages of infection (1-4 days of symptoms) ¹⁹⁰and later (10-14 days of symptoms) suggesting that inflammaging and the innate 191 immune response triggered by COVID-19 indeed overlap later when immunity to 192 infection is stablished.

¹⁹³To help distinguishing between pre-existing inflammaging as a fuel to disease 194 progression and the viral-induced cytokine storm, we studied an important group of 195 patients found in our cohort: the progression group. These individuals were classified as 196 having mild symptoms of COVID-19 when they were recruited (1-4 days of symptoms) 197 but progressed to severe disease and hospitalization during the 14-day-follow-up period. ¹⁹⁸Notably, the overall inflammatory profile of these patients represented by a radar plot ¹⁹⁹(**Figure 1e**) and the comparative analysis of the 10 main plasma mediators (**Figure 1f**) 200 clearly showed that they presented, since the early stages of infection, an inflammatory 201 activation similar to the group of severe COVID-19 patients, and significantly different 202 from Mild and FLS patients. This suggests that the initial immunological imprint of 203 inflammatory mediators can predict disease outcome.

²⁰⁵**Severe COVID-19 was associated with higher inflammatory activation in** ²⁰⁶**individuals from endemic areas for infectious diseases and with biomarkers of** ²⁰⁷**aging.**

²⁰⁸To address the question of how distinct environments influence COVID-19 and ²⁰⁹whether aging biomarkers can be used to distinguish the different clinical forms of 210 disease, we compared the inflammatory profile of adult and elderly individuals with FS 211 or mild COVID-19 from Belo Horizonte and Governador Valadares, an endemic area 212 for several infectious diseases where individuals present an accelerated biological aging
213 ¹⁶. First, we confirmed that there was a clear difference in the global inflammatory 213 $\frac{16}{15}$. First, we confirmed that there was a clear difference in the global inflammatory 214 profiles between individuals with FLS and Mild COVID-19 in the endemic area despite 215 their similarity of symptoms (**Figure 2c**). Moreover, individuals from Governador ²¹⁶Valadares had a higher activation profile when compared to individuals from Belo ²¹⁷Horizonte, and the elderly from the endemic area presented a much higher production of

218 immune mediators than adults (**Figure 2c**). Hence, not only does COVID-19 presented 219 itself as a greater challenge to the immune system than other respiratory infections, but 220 the inflammatory activation at early phase of infection is exacerbated in populations 221 with accelerated biological age.

222 CXCL9 has been recently identified as critical mediator involved in age-related 223. chronic inflammation 36 . Indeed, using this chemokine as a biomarker of aging and 224 frailty, we observed that elderly individuals were higher producers of CXCL9 than 225 adults. Interestingly, both adults and elderly hospitalized patients had a similar and 226 more prominent production of this mediator than individuals with FLS or mild COVID-²²⁷19 (**Figure 2d**). Moreover, elderly individuals presented no difference in CXCL9 ²²⁸production across the spectrum of COVID-19 clinical forms (**Figure 2e**) probably 229 because they already had high baseline levels of this chemokine. Therefore, severe ²³⁰COVID-19 was associated at early stage of infection with increased production of an 231 immunological biomarker of aging.

232 Our data on the inflammatory profile of individuals from endemic and non-233 endemic areas in Brazil suggest a strong and unique association between inflammaging 234 at early stages of COVID-19 to disease progression.

²³⁶**Severe COVID-19 correlated with accumulation of memory, exhausted and** ²³⁷**senescent T cells.**

²³⁸To further explore the association between other features of immunosenescence 239 and COVID-19 outcomes, we investigated changes in the frequencies of T cell 240 populations expressing cell markers of memory, exhaustion, and senescence.

Aging has a great impact in the T cell compartment, especially in $CDS⁺ T$ cells 242³⁷. To investigate variations in the frequencies of functional subsets of T lymphocytes, 243 multiparametric flow cytometry analyses was performed using a panel of monoclonal ²⁴⁴antibodies to surface markers of exhaustion/senescence in these cells (**Supplementary** ²⁴⁵**Table 2**). Gating strategies for all cell populations are shown in **Supplementary Figure** ²⁴⁶**3**.

247 To investigate immunophenotypes of T lymphocytes, $CD4^+$ and $CD8^+$ T cells ²⁴⁸were studied as global main subpopulations and segregated into functional subsets of

naïve $(CD45RO⁺CCR7⁺$ effector (CD45RO⁻CCR7⁻), 249 naïve (CD45ROCCR7⁺), effector (CD45ROCCR7⁻), central memory 250 (CD45RO⁺CCR7⁺), effector memory (CD45RO⁺CCR7) T cells. We identify 251 accumulation of several subsets of $CD8⁺$ and $CD4⁺$ T cells expressing markers of ²⁵²exhaustion and senescence in patients with severe COVID-19 (**Figure 3**). Concerning $CD8^+$ T cell analysis, individuals with severe disease had higher frequencies of $CD8^+$ T 254 cells expressing biomarkers of senescence (TIGIT) and exhaustion (ICOS). Effector CD8⁺ ²⁵⁵T cells expressing PD-1 were also augmented in severe diseased patients (**Figure 3 a, b**). In addition, $CD8^+$ T cells with senescence/ exhaustion phenotypes accumulate in 257 individuals of this group: $CD28-PD-1^+CD57^+CD8^+$, $CD28^+KLRG1^+CD8^+$, $CD28^-PD-$ 258 1⁺CD8⁺, CD28⁻KLRG1⁺ PD-1⁺ CD8⁺, KLRG1⁺PD-1⁺CD8⁺, KLRG1⁺PD-1⁺CD8⁺, 259 TIGIT⁺ICOS⁺ CD8⁺ and CD28-PD-1⁺ effector and effector memory CD8⁺ T cells **260** (**Figure 3 c, d**). For CD4⁺ T cells, we also found higher frequencies of cells expressing 261 the senescence marker TIGIT and of cells expressing the mixed senescence/exhaustion 262 phenotype: $TIGIT⁺ICOS⁺CD4⁺, CD28⁻CD57⁺KLRG1⁺CD4⁺ and CD28⁻CD57⁺KLRG1⁺$ 263 effector memory CD4⁺ T cells (**Figure 3e, f**). For some specific sub-populations of 264 senescent $(CD4^+TIGIT^+)$ (**Figure 3e**) and senescent/exhausted $(CD28^{\circ}PD-1^+$ effector 265 and effector memory CD8⁺, TIGIT⁺ICOS⁺CD4⁺) T cells (**Figure 3c**), a significant 266 difference between patients with mild and moderate disease was observed. Therefore, 267 along with an exuberant inflammaging, COVID-19 patients exhibited an accrual of 268 senescent/exhausted $CD8^+$ and $CD4^+$ T cells that make up the scenario of dysfunctional 269 immunity permissive to disease progression.

²⁷¹**Severity of COVID-19 was associated with a reduction in B cell diversity and** ²⁷²**higher maturation of the immunoglobulin repertoire.**

²⁷³To study the B cell senescence, we examined the immunoglobulin repertoire in a 274 set of 45 individuals from individuals in Belo Horizonte and Governador Valadares ²⁷⁵(endemic area) who were either uninfected or tested positive for COVID-19. Within 276 these cities, participants were categorized into negative group $(n=6)$, mild COVID-19 277 group $(n=19)$, and hospitalized COVID-19 group $(n=20)$ of individuals from Belo ²⁷⁸Horizonte and São Paulo along with mild COVID-19 individuals from Governador 279 Valadares. The sequencing resulted in 285,341 to 1,525,890 raw reads. After pre-280 processing, 130,060 to 548,060 annotated reads and 3,053 to 69,737 clones were 281 obtained (**Supplementary Table 3**).

²⁸²Antibody repertoire diversity within the top 100 most expanded clones among 283 individuals in Belo Horizonte showed that the Shannon entropy diversity was lower in 284 the hospitalized individuals as compared to both mild COVID-19 and control groups ²⁸⁵(**Figure 4b**). **Figure 4c** also shows that hospitalized individuals had a more mature 286 repertoire with highly mutated VH immunoglobulin genes and lower frequencies of 287 germline-encoded antibodies, a phenotype of an aged repertoire. A graphical 288 representation of clonal expansion at day 2 and 7 of symptom onset shows that in both 289 periods the clones from severe individuals are distinct from baseline (negative) and 290 clones from mild individuals (**Figure 4a**).

 $\overline{}$

²⁹²**Acceleration of biological age was detected in hospitalized individuals with** ²⁹³**moderate/severe COVID-19**

²⁹⁴To further explore our hypothesis, we accessed the DNA methylation status of 295 peripheral blood mononuclear cells to investigate whether COVID-19 severity was 296 associated with acceleration of biological age. We used the cohort of individuals that 297 had been already investigated for the inflammatory and phenotypic lymphoid profiles 298 and performed the analysis using different biological age acceleration clocks $16,38$.

For this analysis, a negative population was selected as a control. Individuals in this group had no symptoms of infection and were negative for SARS-CoV-2 by RT-PCR (**Table 1**). Negative individuals were compared to infected patients with Mild COVID-19 and a Hospitalized COVID-19 group of patients with either moderate or severe clinical disease. Several clocks are now available to access aging acceleration 304 using different gene clusters. We used seven clocks proposed by Horvath 38 , Horvarth 305 Updated, Levine 39 , Hannum 40 , TL 41 , BLUP, EN, Wu 25,42 , to obtain more accuracy in 306 detecting acceleration or deceleration of biological age.

³⁰⁷Based on data previously published by our group showing that the population of 308 Governador Valadares presents an acceleration of biological age 16 , we decided not to ³⁰⁹use these individuals in the initial analysis, so that we could focus on understanding the ³¹⁰association between age acceleration and disease severity (**Figure 4D**). Notably, 311 individuals of the hospitalized group had an increase in biological age when compared 312 to the mild COVID-19 group (in Horvarth (Updated), Levine, EN, BLUP and TL ³¹³watches) and to the negative group (in Horvarth, Horvarth (Updated), Hannum, BLUP

³¹⁴and EN watches) (**Figure 4D**). The Wu clock was the only one of the analysed watches 315 that showed no difference among groups. Next, we analyzed the total population, 316 including individuals from Governador Valadares, and the result was similar (**Figure** ³¹⁷**4E**) except for the TL clock that showed no difference among groups.

318 Network analysis is a powerful tool for understanding the complex relationships 319 between variables within a system. By constructing a network representation, we can 320 visualize and analyze the interconnections between different components. In our study, ³²¹we employed a weighted network analysis to investigate the correlations between ³²²biologically relevant markers associated with cytokines/chemokines and cellular 323 proteins that are markers of senescence and exhaustion. Individuals who developed 324 severe COVID-10 had a more connected senescence/exhaustion network than ³²⁵individuals that developed mild COVID-19 (**Figure 4F**). Among the more connected 326 clusters, senescent and exhausted T cells are dominant. A graphical representation of all ³²⁷data obtained on the senescence profile illustrates the general conclusion that patients 328 with severe disease resemble the aging phenotype (**Figure 4G**).

³²⁹Therefore, our data clearly correlate several features of the immunosenescence 330 profile including inflammaging, increased frequencies of senescent/exhausted T cells, 331 oligoclonality of B cell repertoire and finally an acceleration of biological age ³³²suggesting that this dysfunctional immune profile can explain, at least in part, the high 333 susceptibility of aged people to develop severe forms of COVID-19.

334

³³⁵**Discussion**

336 Since the beginning of the SARS-CoV-2 pandemic, the elderly have been the main risk group for the mortality and the severe clinical outcomes of COVID-19^{2}. ³³⁸Several review articles have proposed that remodelling features acquired by the aging 339 immune system such as the inflammaging phenomenon and dysfunctional immunity 340 might have a major role in the unfavourable outcome of the disease in older individuals $4,21-24,43$. Besides these theoretical proposals, some studies have addressed the ³⁴²hypothesis in experiments using senolytics in aged mice infected with a SARS-CoV-2– 343 related virus⁴⁴ and in individuals with severe and critically ill COVID-19 patients by 344 analyzing exhausted/senescent T cells $45,46$ and age-acceleration clocks 25 .

³⁴⁵In our study, we used more than one approach to reach a reliable conclusion 346 when testing our hypothesis, we distinguish patients with mild disease from those ³⁴⁷severely ill to investigate the effect of aging phenotype in the disease outcome and we 348 specifically restrict our sample to early infected patients (1-4 days of symptoms), a 349 period when senescent and exhausted T cells are at baseline frequencies (a small 350 percentage of the overall cell population) in mild COVID-19²⁷. Our group and others 351 have shown that SARS-CoV-2 infection induces not only a systemic inflammatory response similar to the inflammaging⁴⁷ but it also leads to the emergence of exhausted 353 and senescent T cells after a period of infection as short as 7 days $27,45$. In addition, we 354 included volunteers with mild flu-like symptoms who tested negative for SARS-CoV-2 ³⁵⁵as a control since these individuals did not show accumulation of exhausted/senescent 356 cells even after 7 days of infection. At this stage, there is probably an overlap between ³⁵⁷inflammaging and innate cytokines/ chemokines produced in the early response to SARS-CoV-2⁴⁷ because these two responses share a set of mediators including IL-6, CXCL8, C-Reactive Protein (CRP), TNF, IL-1β, IL-10, IL-1Ra IL-12p70, IFN-γ^{6,10}.

360 Ten mediators were consistently identified in all COVID-19 patients with 1-4 361 days of symptoms, and they were detected at variable levels depending on the clinical 362 form of the disease. Most of them are proinflammatory mediators (CCL2, CXCL8, 363 CXCL10, IL-1 β , IL-6, TNF, IFN- γ , IL-12p70) that contribute to both frailty in the $B = 364$ elderly $10,36,48$ and to a series of pathological events seen in COVID-19 such as 365 thrombosis of blood capillaries, congestion of the alveolar wall, inflammatory ³⁶⁶infiltration, formation of hyaline membrane in the alveoli, pulmonary edema, and severe 367 respiratory failure $5,49$ whereas others play an anti-inflammatory and regulatory role (IL- 368 IRa and IL-10) in both conditions. Interestingly, even though other viral infections can 369 induce a burst of innate cytokines/chemokines during the first few days of infection 47 , 370 the inflammatory signature observed in individuals with mild COVID-19 and Flu-like 371 syndrome in our study were not equivalent (**Figure 1c, d, Supplementary Figure 1**). ³⁷²This finding underscores the uniqueness of SARS-CoV-2 infection and suggests that the 373 overlap between innate response to the virus and the pre-existing inflammaging 374 phenomenon is of particular importance to COVID-19 with predictive value for the 375 outcome of the disease. A further demonstration of that is the data collected from 376 individuals in the Progression group (**Figure 1e, f**) that clearly showed an inflammatory 377 signature of severe disease at early stages of infection when symptoms are still mild.

378 Another distinctive feature of our study population was the inclusion of a group 379 of patients from an endemic region for infectious diseases in Brazil (Governador ³⁸⁰Valadares, MG). This group allowed us to examine the impact of accelerated 381 imunosenescence and other changes favourable to the senescence process $16,18$ in ³⁸²COVID-19 development. Indeed, we found a more prominent inflammatory profile in 383 patients from the endemic area even in the mild COVID-19 and flu-like syndrome ³⁸⁴groups and this hyperactivation was exacerbated in the elderly (**Figure 2 a-c,** ³⁸⁵**Supplementary Figure 1**). These set of results highlight two important aspects 386 concerning infectious diseases. First, it demonstrated that there is a variability of 387 immune responses to a single pathogen, even for those with the same spectrum of ³⁸⁸symptoms, and this may be determined by genetic and environmental conditions as 389 previously proposed 50 . In addition, it suggests that individuals living in areas of high 390 antigenic burden, despite their accelerated senescence profile 16 , may also develop 391 mechanisms of inflammatory remodelling resembling the ones observed in centenarian 392 populations of Italy $6,48$ and aged populations in Brazil $17,37$. These mechanisms would ³⁹³allow them to successfully cope with life-threatening infectious disease such as 394 COVID-19.

³⁹⁵Several age clocks based on different biological parameters have been proposed 396 $38-40,42$ and a recent study developed an inflammatory clock (iAge) based on patterns of systemic age-related inflammation tagged to multimorbidity and frailty in the elderly 36 . ³⁹⁸The strongest contributor to iAge was CXCL9, a chemokine involved in cardiac aging 399 and impaired vascular function. Interestingly, CXCL9 is analogous to and from the 400 same family of CXCL10, a mediator highly associated with severity of COVID-19⁵¹ ⁴⁰¹(**Figures 1 and 2**). CXCL9 was found at high levels in hospitalized (**Figure 2d**), 402 severely diseased (**Figure 2e, f**) patients and in the elderly from Belo Horizonte and ⁴⁰³Governador Valadares regardless of their infection status (**Figure 2d**). Therefore, at 404 early stage of infection, severe COVID-19 could be distinguished from other clinical 405 forms of the disease by a strong biomarker of aging.

406 Alongside with the inflammaging phenomena, immunosenscence is marked by ⁴⁰⁷several changes in innate and acquired immunity being lymphocytes and the T cell 408 compartment the most affect ones. During aging, thymic atrophy, sustained replicative 409 pressure due to homeostatic proliferation and clonal expansion after antigenic 410 stimulation leads to the emergence of terminally differentiated T cells such as exhausted

⁴¹¹and senescent cells. Although these T cell populations share common features such as 412 functional remodelling and cell cycle arrest, they have also distinctive characteristics 52 . ⁴¹³Chronically stimulated T cells during aging, persistent viral infections and cancer 414 trigger an exhausted profile characterized by the expression of inhibitory receptors such 415 as programmed cell death protein 1 (PD-1) $53,54$, inducible costimulatory molecule 416 (ICOS) $53,54$ and T-cell immunoglobulin and immunoreceptor tyrosine-based inhibitory 417 motif domain (TIGIT) 55 . Exhausted T cells display a dysfunctional and non-⁴¹⁸proliferative state that is reversible. On the other hand, immune and non-immune ⁴¹⁹senescent cells present a non-reversible loss of their proliferative capacity and acquire a 420 senescence associated secretory phenotype $(SASP)$ that contributes to inflammaging 56 . 421 Expression of CD57⁵⁶ and killer cell lectin-like receptor G subfamily member 1 422 (KLRG1) 56 as well as the loss of the co-stimulatory molecule CD28⁵⁶ are considered 423 indicators of terminal differentiation and are associated with the senescence profile of T ⁴²⁴lymphocytes. Although KLRG1 also emerges on the cell surface after differentiation, 425 the signalling generated by this molecule regulates a pathway related to exhaustion, 426 making it a marker of both cellular senescence and exhaustion 56 .

427 Notably, we also detected, in patients with severe COVID-19, an accrual of CD8⁺ ⁴²⁸T cells expressing markers of senescence (TIGIT) and exhaustion (ICOS) (**Figure 3a, b**) as well as increase in frequencies of senescent $CD4^+TIGIT^+T$ cells. Using CD28, 430 KLRG1, CD57, TIGIT, PD-1 and ICOS as biomarkers, higher frequencies of $CD8⁺$ and 431 $CD4^+$ T cells with mixed senescence/ exhaustion phenotypes were also observed 432 individuals with severe COVID-19 when compared to individuals with mild disease ⁴³³and, for specific phenotypes, to individuals with moderate disease (**Figure 3**). This ⁴³⁴association of T cell senescence to COVID-19 severity further confirmed our hypothesis ⁴³⁵and prompt us to examine other parameters of aging as risk factors for the worse disease 436 outcomes.

⁴³⁷To further understand the influence of B cell senescence in SARS-CoV-2 438 infection, we explored the immunoglobulin repertoire of COVID-19 patients and 439 healthy individuals. Aging is associated with decreased lymphoid differentiation and 440 with a consequent reduction in the output of naïve B cells. Clonal expansion of ⁴⁴¹memory-like B cells in the periphery due to homeostatic proliferation and chronic 442 stimulation by antigens result in maturation and shrinkage of the immunoglobulin 443 repertoire 7,8 . Herein, we analyzed the most expanded clones to have a better grasp of

⁴⁴⁴their representation in the overall repertoire. As shown in **Figure 4a**, the most expanded 445 clones were not as dominating in individuals who tested negative for the disease when 446 compared to the one who had a mild outcome. Also, we observed that individuals who ⁴⁴⁷were hospitalized had the most expanded clones representing a larger amount of the 448 repertoire. In addition, hospitalized patients had lower repertoire diversity when ⁴⁴⁹compared to both negative and mild COVID-19 individuals (**Figure 4b**). These results 450 correlated with previous reports demonstrating that the more severe the COVID-19 the 451 lower the diversity of the antibody repertoire $57,58$. In addition, the immunoglobulin ⁴⁵²repertoire of individuals who needed to be hospitalized had a more mature profile ⁴⁵³(**Figure 4c**) characterized by altered immunoglobulin gene usage and an increased ⁴⁵⁴frequency of mutated antibodies structurally diverging from their germline precursors. ⁴⁵⁵Mature repertoires are indicators of immunosenescence because mutations accumulated 456 with age as the frequency of germline-encoded antibodies decrease δ .

⁴⁵⁷To further explore the idea that individuals who developed severe COVID-19 ⁴⁵⁸might have an immunosenescent phenotype, we sought to investigate the biological age 459 of individuals within our cohort measuring DNA methylation in CpG dinucleotides. ⁴⁶⁰Many studies have used DNA methylation as an epigenetic clock to measure biological 461 age since DNA methylation accumulates with aging 38 . The epigenetic age can be 462 accelerated by certain diseases including HIV infection, Alzheimer's, obesity, and by 463 chronic exposure to infectious agents even when the individuals are not infected^{42,16}.

⁴⁶⁴To increase the accuracy in measuring biological age by an epigenetic approach, ⁴⁶⁵we analyzed the DNA methylation data using 8 different clocks: the classic and updated 466 Horvarth clocks⁵⁹, Hannum's, Levine's, the BLUP, Wu, EN and TL clocks, the latter ⁴⁶⁷focused on CpGs associated with telomere formation, expression, and 468 maintenance^{27,43,46}. Our results show an acceleration of epigenetic age in hospitalized 469 patients with severe COVID-19 in 7 of the 8 analyzed clocks if we exclude individuals 470 from Governador Valadares. Including this population, we found a similar profile result ⁴⁷¹(**Figure 4d**) with a variation in one of the clocks. However, there is an increase in 472 statistical significance in the analysis when individuals from the endemic area were ⁴⁷³included (**Figure 4e**). Thus, these data confirmed, by another approach, the tight 474 association between the immunosenescence phenotype and COVID-19 severity. ⁴⁷⁵Moreover, a network analysis of integrated data on the immunosenescence profile 476 showed that individuals who developed severe COVID-19 had clusters with higher

⁴⁷⁷degree of integration mostly among senescent and exhausted of T cells (**Figure 4 f**). A 478 graphical representation of all data illustrates that individuals with severe disease 479 resemble the aged phenotype (**Figure 4 g**).

480 There were limitations in this study. Although we included only individuals with 481 initial infection (1-4 days of symptoms), we cannot exclude the overlap between the 482 inflammatory mediators coming from a previous state of inflammaging from the early 483 innate response to SARS-CoV-2. This was less relevant for the analysis of senescent ⁴⁸⁴and exhausted T cells because we have shown that COVID-19 can induce senescence 485 and exhaustion in $CD8^+$ and $CD4^+$ T cells after 7 days of symptoms ²⁷. It is probably the 486 case of the repertoire analysis of antibodies that are very unlikely to have expanded due 487 to virus stimulation in such short time of infection. However, the choice of working 488 with individuals within 1-4 days of symptoms and the need to match all the individuals 489 by sex, age and presence of comorbidities reduced our study sample, which was another 490 limitation.

491 Despite these restrictions, our data clearly show a close association between a ⁴⁹²profile of immunosenescence, examined by different approaches and consolidated by 493 network analysis, and the progression of early phase infected individuals to severe ⁴⁹⁴COVID-19. We also reached important non-anticipated conclusions such as the 495 uniqueness of the inflammatory pattern associated with early COVID-19 when 496 compared to other respiratory infections and the differences in the inflammaging and ⁴⁹⁷immunesenescence phenotype in endemic regions for infectious disease when compared 498 other metropolitan areas. These results are relevant not only to uncover the pathogenesis 499 of severe COVID-19, but they have also predictive value for future epidemic viral 500 infections. Most of all, the data shed light on the aging process and on the consequences 501 of accelerated senescence that affect certain endemic regions of the planet.

502

⁵⁰³**Author contribution:**

⁵⁰⁴A.M.C. designed the study, coordinate the recruitment and analysis, and wrote the 505 manuscript; L.H.A.V. and L.T. performed sample collection and processing, Luminex 506 and flow cytometry analysis, and wrote the manuscript; G.C.C. performed the 507 recruitment, blood collection and sample processing of the volunteers in Belo ⁵⁰⁸Horizonte, discussed the results and wrote the manuscript; J.Z. performed flow

509 cytometry analysis of samples from São Paulo and discussed the results, M.M.C. 510 performed DNA methylation analysis and discussed the results; C.H.R-P. was in the 511 charge of sample processing and helped with the flow cytometry analysis, J.G. 512 performed the B cell repertoire analysis and discussion under the supervision of L.F.F., ⁵¹³F.C.M. performed the bioinformatic analysis and discussed the results; L.N. developed 514 the database for the study, M.A.O., V.D.M. and M.F.O. helped in sample processing, 515 Luminex analysis and discussion of the results, L.W.Z. helped with B cell repertoire and ⁵¹⁶DNA methylation analysis and the discussion of the results; M.S.C. performed the 517 clinical exams of volunteers at UPA-Centro Sul in Belo Horizonte under the supervision 518 of U.T.; H.I.S. performed the RT-PCR tests of all volunteers under the supervision of 519 S.M.R.T.; H.C.G. and R.C.B. were in charge of clinical exams of volunteers recruited at ⁵²⁰Hospital Universitário Risoleta Tolentino Neves in Belo Horizonte; A.P.V., N.A., ⁵²¹G.P.C. and S.R. were in charge of clinical exams of volunteers recruited at Instituto de ⁵²²Infectologia Emílio Ribas, M.L.O.J. was in the charge of the clinical exams of 523 volunteers recruited at Hospital Unimed in Governador Valadares; A.P.C.B. helped in 524 the recruitment and sample processing of volunteers in Governador Valadares; F.F.C. 525 helped in recruitment, sample collection and processing in Belo Horizonte; E.S.F. 526 helped with the Luminex testing and data analysis supervised by O.A.M.F.; V.C. helped 527 in the bioinformatic and statistical analysis as well as the discussion of the results, R.A. 528 was in the charge of radiographic classification and follow-up of hospitalized patients in 529 São Paulo; R.S. helped in the recruitment of healthy volunteers in São Paulo; G.S-N. 530 coordinate all the recruitment and sample collection/processing of volunteers from 531 Governador Valadares and helped in the statistical analysis; M.A. and C.L. helped in 532 sample processing and the flow cytometry analysis of volunteers from São Paulo, ⁵³³T.U.M. coordinate the recruitment, questionnaire application and telemonitoring of 534 volunteers of Belo Horizonte and helped discussing the data; D.M.F. coordinate sample 535 processing and flow cytometry analysis in São Paulo, helped designing the experiments 536 and discussing the data; A.T-C. supervised the flow cytometry analysis, Luminex ⁵³⁷analysis, serology tests in Belo Horizonte, helped designing the experiments and 538 discussing the data.

539

⁵⁴⁰**Acknowledgments:**

541 This study was supported by grants from Merck Dohme & Sharp (MISP#60383), ⁵⁴²Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq, Brazil, ⁵⁴³407363/2021-1), Coordenação de Aperfeiçoamento de Pessoal do Ensino Superior ⁵⁴⁴(# 0688/2020, CAPES, Brazil) and Pro-reitoria de Pesquisa da Universidade Federal de 545 Minas Gerais (PRPq-UFMG). A.M.C.F., A.T-C., D.M.F., T.U.C., O.A.M.F., G.C.C., ⁵⁴⁶M.M.C., M.A.O., M.F.O., V.D.M. are recipients of research fellowships and 547 scholarships from CNPq, L.H.A.V., L.T., L.N. are recipients of scholarships and ⁵⁴⁸fellowships from CAPES, Brazil, F.C.M. is recipient of a scholarship from Fundação de ⁵⁴⁹Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG, Brazil), M.A. and C.L. are 550 recipients of a scholarships from Fundação de Amparo à Pesquisa do Estado de São 551 Paulo (FAPESP, Brazil).

552

⁵⁵³**Conflict of Interest Statement**

- ⁵⁵⁴The authors do not have any conflicts of interest regarding this manuscript, its
- 555 preparation, or the research that went into it.
- 556

⁵⁵⁷**Data availability statement**

- ⁵⁵⁸The MiAIRR data that support the findings of this study are available in Zenodo with
- 559 the identifier(s) doi:10.5281/zenodo.12789370. FASTQ files can be accessed via NCBI
- 560 under the BioProject accession PRJNA1138747 or SRA SRP528303, in the project
- 561 Immunosenescence of antibody repertoire in individuals from endemic areas for
- 562 infectious diseases or via the link:
- 563 https://www.ncbi.nlm.nih.gov/bioproject/PRJNA1138747.
- 564 Data are also available upon request to the corresponding author.
- 565

⁵⁶⁶**Materials and Methods**

⁵⁶⁷*Ethics Statement*

568 The present study was approved by the national research ethics committee in ⁵⁶⁹Brazil (CONEP) and by the research ethics committees of the Universidade Federal de 570 Minas Gerais (UFMG), and of the Instituto de Infectologia Emílio Ribas (IIER) (CAAE ⁵⁷¹40208320.3.2001.0061). All participants signed the informed consent form during the 572 first evaluation, agreeing to participate in the study.

573

⁵⁷⁴*Study Population and Data Collection*

575 A total study sample of 806 volunteers were recruited in 3 cities, Belo 576 Horizonte/MG (467 individuals), Governador Valadares/MG (176 individuals) and São ⁵⁷⁷Paulo/SP (163 individuals) from December 2020 to October 2021 (**Table 1 and 2**). The 578 strains that circulated during the period were the original and P1 (Brazilian variant). 579 Individuals with symptoms of a flu-like syndrome of unknown ethiology and healthy 580 individuals were used as study controls. Volunteer recruitment in Belo Horizonte (MG) ⁵⁸¹was carried out at the Health Care Unit in the Center-South region (UPA-CS), at ⁵⁸²Hospital Risoleta Tolentino Neves, at Casa do Ancião in Cidade Ozanam and at home. ⁵⁸³In São Paulo (SP), volunteer recruitment and sample collection took place at the ⁵⁸⁴Instituto de Infectologia Emílio Ribas (IIER) and in Governador Valadares (MG), at ⁵⁸⁵Hospital da Unimed de Governador Valadares and at home for some exceptional cases. ⁵⁸⁶A study flowchart with an outline of recruitment and sample collection at the health 587 units is shown in **Supplementary Figure 4**. All individuals had their blood collected ⁵⁸⁸and were tested using nasopharyngeal swabs samples for reverse-transcriptase 589 quantitative polymerase-chain-reaction (RT-qPCR) detection of SARS-CoV-2. They ⁵⁹⁰were telemonitored for 14 days to obtain information on their clinical status. 591 Hospitalized individuals had their clinical evolution information collected directly from 592 their medical records. All volunteers had their weight and height measured to determine 593 their nutritional status by using the Body Mass Index (BMI) ratio. Weight was assessed 594 using a Balmark \circledR device with a capacity of 200 kg and an accuracy of 100 g, while 595 height was measured with a portable stadiometer that accommodates up to 2 meters 596 with an accuracy of 1.0 mm. The Body Mass Index (BMI) was calculated using the 597 formula: BMI = weight (kg) / height² (m) and was subsequently classified according to 598 their age range, based on the World Health Organization scale 60 . A clinical and ⁵⁹⁹sociodemographic questionnaire was also administered during recruitment to gather ⁶⁰⁰additional information, such as current symptoms, days since symptom onset, 601 vaccination status, and medical history.

602

⁶⁰³*Study inclusion and exclusion criteria*

⁶⁰⁴Initially, the inclusion criteria for the study groups were all individuals over 20 605 years of age who had flu-like symptoms at the time of data collection. For negative 606 individuals, the inclusion criterion at recruitment was all individuals who were never 607 diagnosed with COVID-19 nor had flu-like symptoms with a confirmed negative RT-⁶⁰⁸PCR test for SARS-CoV-2 infection and who tested negative for serological 609 quantification of the following 4 viral proteins: spike 1, spike 2, nucleocapsid and 610 receptor binding domain (RBD).

611 Exclusion criteria were applied to any patient who took any dose of the COVID-⁶¹²19 vaccine, patients living with HIV, those with inconclusive RT-PCR test, missing ⁶¹³important information in their medical records or in the health questionnaire, those with 614 greater than 4 days of symptom onset and those with a positive anti-SARS-CoV-2 IgG 615 or IgM serology. We included only individuals who had 1 to 4 days of symptoms to 616 better assess possible predictors of the disease. As shown previously by our group, 617 individuals with mild and severe COVID-19 presented an increase in the frequency of 618 exhausted/senescent T cells and in the levels of inflammatory mediators after 7 days of 619 symptoms with a clear difference between the ones with only 4 days of symptom 620 ω onset²⁷.

⁶²²*Clinical Groups and Criteria for Classification of COVID-19 Patients*

623 We classified those infected with COVID-19 (positive RT-PCR for SARS-CoV-⁶²⁴2) into different clinical forms of COVID-19 (mild, moderate and severe) according to ⁶²⁵WHO criteria (**Supplementary Table 1**). To perform certain analysis, we chose to 626 group individuals with a moderate or severe clinical form of COVID-19 in a single 627 group called Hospitalized since these individuals needed inpatient care. Individuals with 628 flu-like symptoms who presented a negative RT-PCR and serological test for SARS-⁶²⁹CoV-2 were grouped in the flu-like syndrome (FLS) group. A group of negative 630 individuals was used in some analysis, and it consists of individuals with a negative 631 SARS-CoV-2 test and no report of flu-like symptoms.

 $\overline{}$

⁶³³*RT-PCR for SARS-CoV-2 detection and viral load calculation*

⁶³⁴RNA extraction from nasopharyngeal swab samples was performed using the 635 QIAamp Viral RNA Mini Kit (Qiagen, Germany) according to the manufacturer's 636 protocol. From 1 mL of Viral Transport Medium containing the collected sample, $47 \mu L$ 637 of each individual sample was pooled in 1.5 mL microtubes, and 150 μ L of the pool ⁶³⁸was used for extraction; the remainder was stored at −80 °C for possible repetitions. In 639 cases where the clustering resulted in detectable results, it was necessary to individually 640 process all samples present in the respective cluster. RT-qPCR was performed using the 641 QuantStudio™ 3 and 5 real-time PCR systems (Applied Biosystems™, United States). 642 For viral RNA detection, the recommendations described by the Charité protocol 61 643 were followed, which targets the gene (E) encoding the viral envelope protein, with a 644 reported sensitivity of 3.9 copies of the SARS-CoV-2 genome per reaction 61 . Thermal 645 cycling was performed at 55 \degree C for 10 min for reverse transcription, followed by 95 \degree C 646 for 3 min and then 45 cycles of 95 \degree C for 15 s, 58 \degree C for 30 s. For endogenous control of 647 the reaction, the gene encoding human RNaseP was used as a target.

648

⁶⁴⁹*Blood collection and isolation of PBMC*

⁶⁵⁰Peripheral blood mononuclear cells (PBMC) were obtained by blood collection 651 from COVID-19 and control patients using heparinized vacuette. The purification was 652 attained by Ficoll gradient (Histopaque -1077 ; Sigma) centrifugation at room 653 temperature, in a 1:2 ratio, for 40 minutes, at 1400 resolutions per minute (RPM) ⁶⁵⁴without breaking. After that, PBMCs were collected using a Pasteur pipette, washed 655 with RPMI medium at 500x for 7 minutes at $4^{\circ}C$, and then red cells were lysed using a 656 lysis buffer. A second wash using RPMI was conducted. Cells were counted and stored 657 in fetal bovine serum supplemented with 10% dimethyl sulfoxide at $-80\degree$ C until use. 658 Samples were processed up to 48 hours after collection.

659

⁶⁶⁰*Plasma and Serum Isolation*

661 Blood was collected into heparin tubes for plasma obtention, and in serum 662 separator tubes containing clot activator. Plasma and serum samples were isolated after 663 whole blood centrifugation at 3000 RPMs for 10 minutes at 20° C, then carefully split 664 into 2mL aliquots and stored at -80°C until the time of testing, Samples were processed 665 up to 48 hours after collection.

666

⁶⁶⁷*Measurement of cytokines, chemokines, and growth factors by Luminex-Multiplex*

The measurement of biomarkers was performed in heparinized plasma for 669 detection and quantification of analytes for all 309 individuals from Belo Horizonte, São Paulo and Governador Valadares (endemic area) all in Brazil. The Bio-Rad 671 Laboratories kit (Bio-Plex® Pro Human Cytokine Standard) was used, allowing for the analysis of several analytes to be analyzed simultaneously, using the magnetic immunoassay technique carried out with the Luminex equipment (Bio-Plex® 200, Bio-Rad), following storage and processing protocols standardized by the Grupo Integrado de Pesquisa com Biomarcadores (GIPB) (IRR-FIOCRUZ/MG). Samples were 676 transported and stored at a temperature of -80° C. Analyses were performed using 677 Bioplex[™] xPONENT version 3.1 software (Bio-Rad), and presented the following panel of analytes: IL-1β, IL-1Ra, IL-2, IL-4, IL-5, IL-6, IL-7, CXCL8, IL-9, IL-10, IL-12p70, IL-13, IL-15, IL-17A, CCL11, Basic-FGF, G-CSF, GM-CSF, IFN-γ, CXCL10, 680 CCL2, CCL3, CCL4, PDGF-BB, CCL5, TNF and VEGF.

681 In all the inflammatory analysis carried out in the present study, we identified 10 682 of the 27 mediators evaluated as those that are most present in the analyses, configuring 683 a possible signature of these mediators in our population (CCL2, CXCL8, CXCL10, IL-684 6, IL12(p70), IFN- γ , IL-1Ra, IL-10, TNF, IL-6) and in order not to dilute the data, we 685 chose to show the differences only within this signature.

⁶⁸⁷*Measurement of chemokines by Cytometric Bead Array (CBA)*

688 The CBA assay was performed using the BD Cytometric Bead Array (CBA) – 689 Human Chemokine Kit to complete the Luminex Bio-plex assay biomarker panel. The 690 chemokines present in the kit are CCL2, CCL5, CXCL8, CXCL9 and CXCL10. 691 Samples from Belo Horizonte-MG, Governador Valadares-MG and São Paulo-SP, all 692 previously prepared before the test, were included. Kit reagents were previously filtered, ⁶⁹³and kit protocol was standardized and used. Samples were purchased from BD 694 FACSVerse.

695

⁶⁹⁶*Measurement of SARS-CoV-2 viral proteins by Luminex-Multiplex*

697 The measurement of biomarkers was performed in serum for detection and 698 quantification of proteins for 144 negatives individuals from Belo Horizonte, São Paulo 699 and Governador Valadares (endemic area) all in Brazil. The Bio-Plex Multiplex SARS-⁷⁰⁰CoV-2 Serology Assay Kit was used, allowing the analysis of the following viral 701 proteins: Spike 1, Spike 2, Nucleocapsid and receptor binding domain (RBD). All ⁷⁰²samples were analyzed simultaneously using the magnetic immunoassay technique 703 performed with the Luminex equipment (Bio-Plex® 200; Bio-Rad) and according to the
704 storage and processing protocols standardized by the Grupo Integrado de Pesquisa com ⁷⁰⁴storage and processing protocols standardized by the Grupo Integrado de Pesquisa com 705 Biomarcadores (GIPB) (IRR - FIOCRUZ/MG). Samples were transported and stored at 706 -80°C. Analysis were performed using Bioplex™ xPONENT software version 3.1 (Bio-707 Rad).

708

⁷⁰⁹*Measurement of Vitamin D*

710 The biochemical test to measure vitamin D levels was outsourced to a clinical 711 analysis laboratory in Belo Horizonte, which has all the laboratory quality certifications 712 in order. The serum levels of this vitamin were measured by chemiluminescence using 713 the Atellica Siemens device. All tests were performed respecting the transport and 714 storage conditions established by the outsourced company.

715

⁷¹⁶*Immunophenotype by polychromatic flow cytometry*

PBMCs (1×10^6) were first stained with LIVE/DEAD fixable aqua dead cell stain (ThermoFisher Scientifc, cat #L34957) and with fluorophore-conjugated monoclonal 719 antibodies to human surface markers. All information on the antibodies, their concentrations, manufacturer and catalogue numbers can be found in **Supplemmentary Table 2**. After the surface staining, cells were fixed and permeabilized using the Foxp3/Transcription Factor Staining Buffer Set from eBioscience (cat #00-5523-00) and stained for -Foxp3 from ImmunoTools (3G3, cat# 21276106) (Supplemmentary Table 2). Single-color labelled cells for fluorescence compensation were prepared with antibody capture compensation beads (BD Biosciences). Cell samples were acquired in a BD LSRFortessa cell analyzer (BD Biosciences) coupled to computers with DIVA and FlowJo-10 *software* (Tree Star). One hundred events for each sample were acquired

728 in the lymphocyte gate. The gate strategy used to analyze T lymphocyte populations is

729 shown in **Supplementary Figure 3**.

⁷³¹*Extraction of DNA and RNA from PBMC and Bisulphite Treatment*

732 Frozen samples of PBMCs were briefly thawed in a 37° C water bath and kept on ⁷³³ice. Pellets were then resuspended in 1ml Trizol and incubated at room temperature. ⁷³⁴Chloroform was then added to each sample. After homogenization and further 735 incubation, samples were centrifuged to form a three-phase solution. The aqueous phase 736 was used for RNA extraction and the interphase was used for DNA extraction. Thus, 737 both samples underwent purification and quantification steps and, after elution, were
738 stored in a -80°C freezer in low-binding plastic microtubes. Genomic DNA extraction stored in a -80°C freezer in low-binding plastic microtubes. Genomic DNA extraction 739 was performed using the QIAamp 96 DNA Blood kit (QIAGEN, Hilden, Germany). 740 DNA $(1 \mu g)$ was bisulphite-converted using the EZ-96 DNA Methylation Kit (Zymo ⁷⁴¹Research, Irvine, USA) with the following modifications: incubation in CT buffer for 742 21 cycles of 15 min at 55 °C and 30 s at 95 °C, elution of bisulphite-treated DNA in 100 743 μl of water. After extraction and conversion, samples were loaded on the Illumina 744 Infinium MethylationEPIC BeadChip.

⁷⁴⁶*Analyses of Epigenetic Aging: Obtaining Raw Methylation Data*

747 DNA from the PBMC samples was extracted according to the Trizol and ⁷⁴⁸chloroform protocol. Subsequently, DNA was hybridized using the Illumina Infinium 749 MethylationEPIC Beadchip (EPIC array) that covers nearly 850,000 CpG sites in the 750 human genome. The watermelon 2.4.0 R package (Pidsley et al., 2013) was used to 751 perform raw data processing, batch effect correction, and obtain matrices with 752 methylation β value. The methylation β value for each CpG site in each sample was 753 calculated to represent the level of methylation.

754

⁷⁵⁵*DNA methylation age calculation*

756 We used the mDNA age of epigenetic clocks created based on blood samples, 757 including the Horvath clock with 353 CpGs based on various tissue types, the

⁷⁵⁸skinHorvath clock that integrated the whole blood dataset with skin, endothelial cells, 759 buccal mucosa and saliva, the Levine clock based on 513 CpGs derived from whole ⁷⁶⁰blood, the TL telomere length clock based on 140 CpGs derived from blood, the BLUP 761 clock based on 319607 CpGs derived from blood, the EN clock based on 514 CpGs 762 derived from all blood and the Hannum watch with 71 CpGs identified in blood DNA ⁷⁶³samples. The deviation between epigenetic age and chronological age, also known as 764 epigenetic age acceleration, was calculated for each sample based on mDNA age regression residuals considering cell counts with the R methylclock 1.5.0 package 62 .

766

⁷⁶⁷*B cells repertoire analysis using immunoglobulin variable heavy chain (IGVH)* ⁷⁶⁸*amplification*

⁷⁶⁹A subset of 45 individuals was analyzed to examine their B cell repertoire. For this, ⁷⁷⁰RNA was extracted from frozen PBMC samples of these individuals using Trizol ⁷⁷¹(ThermoFisher). The cDNA was synthesized with SuperScript IV First-Strand Synthesis 772 System (ThermoFisher) from approximately 500 ng of RNA, following the 773 manufacturer's instructions. IGVH amplification was performed using 0.2 mM of ⁷⁷⁴forward primers (1 to 8; **Supplementary Table 4**), 0.1 mM of each IgG and IgA 775 reverse primers (9 and 10; Supplementary Table 4), 0.2 units (U) of PlatinumTM Taq 776 DNA Polymerase High Fidelity (Invitrogen), 1X High Fidelity PCR Buffer solution, 0.2 777 mM of dNTPs, 1 mM of MgSO₄, and 2 μ L of cDNA in a final volume of 50 μ L. The 778 PCR reaction was conducted using the following program: 2 minutes (min) at 95 °C; 4 779 cycles of 94° C for 30 seconds (sec), 50° C for 30 sec, and 68° C for 1 min; 4 cycles of 780 94°C for 30 sec, 55°C for 30 sec, and 68°C for 1 min; 22 cycles of 94°C for 30 sec, 781 63°C for 30 sec; 68°C for 7 min and final hold at 4°C. Samples GV47, GV50, GV51, 782 GV54, GV92, GV106, GV144, and GV146 were amplified using the NEBNext® High-783 Fidelity 2X PCR Master Mix (New England Biosciences, UK). Forward primers at a 784 final concentration of 0.2 mM, IgG/IgA reverse primers at 0.1 mM, and 2 μ L of cDNA 785 were added to 1x PCR Master Mix in a final volume of 50 μ L. The cycling conditions 786 were the same as described above, except for an extension temperature of 72° C. Four 787 replicates were amplified for each sample. The mixed 200 μ L of PCR product of each 788 sample was precipitated using Puregene® Concentrating DNA protocol (Qiagen, 789 Germany). IgG/IgA amplification was excised from an electrophoresis run of 1% 790 agarose gel, followed by the PCR purification protocol provided by NucleoSpin Gel and

791 PCR Clean \Box up kit (Macherey-Nagel). The concentration of the DNA was calculated

792 using Nanodrop and Qubit DNA High Sensitivity kit (ThermoFisher Scientific).

⁷⁹⁴*Library construction and sequencing*

795 Sequencing libraries were constructed using the Nextera XT DNA Library Prep Kit ⁷⁹⁶(Illumina) according to the manufacturer's instructions. A PCR reaction was prepared to 797 contain: 5 µl of Nextera CD Index 1 (i7) Primer (H7XX); 5 µl of Nextera CD Index 2 798 (i5) Primer (H5XX); 1X of the High-Fidelity PCR Buffer solution; 0,2 mM of dNTPs; 1 799 mM of MgSO₄; 1 U of Platinum[®] Taq DNA High Fidelity Polymerase; 5 µl (if DNA 800 concentration $>= 10$ ng/ μ l) or 10 μ l (if DNA concentration ranged from 5 -10 ng/ μ l) of 801 the gel purified amplicon in a final volume of 50 μ l. The cycling condition was 3 min at 802 95 °C; 12 cycles of 94 °C for 30 sec, 55 °C for 30 sec, and 68 °C for 1 min; 68 °C for 5 803 min; and hold at 4° C. The PCR product was purified with 0.5 volumes of Agencourt ⁸⁰⁴AMPure XP beads and the library was quantified using the Qubit DNA High Sensitivity 805 kit (ThermoFisher Scientific). Amplicon size was inferred using the High Sensitivity 806 DNA Kit (Agilent) run on the Bioanalyzer 2100 (Agilent). Sequencing was performed 807 on the Illumina MiSeq System (Illumina), using the Miseq Reagent Kit v3 (600-Cycle) ⁸⁰⁸(Illumina) with 301 sequencing cycles for each forward and reverse read. A total of 31 809 different libraries from the volunteers were joined equimolarly in a pool of 4nM and 810 diluted to 18 picomolar for further sequencing. A summary of found sequences are in ⁸¹¹**Supplementary Table 4.**

⁸¹³*Bioinformatic analysis: Pre-processing*

814 Samples were demultiplexed by the Illumina sequencer tool or using an in-house script 815 resulting in FASTQ files. All pre-processing was done using the framework 816 Immcantation and it consists of 4 steps: 1) Using pRESTO $⁶³$, the AssemblePairs</sup> 817 module was used to join the sequence, based on the 3'-5' read and the 5'-3' read, with a 818 minimum overlap of 50 nucleotides; 2) Quality filter was applied by using the module 819 FilterSeq 63 Only sequences with a Phred score $>=30$ were selected; 3) The module 820 MaskPrimers 63 was employed to find the primers of the IGHV gene and constant 821 region. The option score was employed, preserving sequences with both forward and

822 reverse primers intact; any sequences not meeting these conditions were filtered out; 4) 823 Annotation was performed with the AssignGenes module from Change-O 63 together 824 with IgBlast $⁶⁴$ to verify similarities between the subject and query. IMGT human</sup> 825 germline was used as a reference for V, J, and D genes, as well as their numbering system 65 ; the MakeDB module was run to organize the alignment into a tabular .tsv file 827 in the MiAIRR format $\frac{66}{ }$. This format contains information on V, D, and J genes and 828 alleles, framework (fw), complementary regions sequences (cdr), and functional status 829 of the sequence (productive or unproductive).

830

⁸³¹*Bioinformatic analysis: Clonotyping and Diversity Analysis*

832 The sequences were grouped into clones using the tool YClon 67 . Shannon diversity was 833 calculated using the *diversity* function of the R package 'vegan' (https://CRAN,R-834 project,org/package=vegan). Diversity was compared between groups of individuals 835 with flu-like symptoms or control $(n=6)$, with the ones with mild COVID $(n=19)$, and 836 severe COVID-19 (n=20) from Belo Horizonte, São Paulo and Governador Valadares ⁸³⁷(only mild cases). Diversity was computed for the 100 most expanded clones from each 838 repertoire. The complete pipeline employed to prepare and analyze the IGH repertoire is 839 available on https://github.com/jao321/covidao.git.

⁸⁴¹*Repertoire Maturity Analysis*

842 We define repertoire maturity as the extent to which an individual's immune repertoire 843 has diverged from germline-like sequences through processes such as somatic ⁸⁴⁴hypermutation and clonal selection. A more mature repertoire is characterized by a 845 lower proportion of germline-like clones, reflecting immune system adaptation and 846 experience with antigens over time. To gain a more profound insight into the maturity 847 of the repertoire, an investigation was conducted to identify the sequence closest to the 848 germline for each clone, encompassing both the V and J genes. To achieve this, we 849 considered the difference in length between the V gene (5 to 6 times longer than the J 850 gene) to ensure a comprehensive analysis, using the following calculation:

851 VJpid =(Vpid *0.8)+(Jpid *0.2)

852 VJpid: Percentage of the expected identity of the V and J genes when compared to the germline

- 853 the germline
854 VJpid: Perce
- 854 VJpid: Percentage of identity of V genes compared to germline
855 VJpid: Percentage of the identity of the J gene when compared to

⁸⁵⁵VJpid: Percentage of the identity of the J gene when compared to the germline

856 Only the sequence with the highest VJpid value for each clone remained, as these sequences have undergone fewer mutations.

- 857 sequences have undergone fewer mutations.
858
-

⁸⁵⁹*Statistical Analysis*

860 The Shapiro-Wilk and Kolmogorov-Smirnov tests were applied to determine whether 861 the data had a normal (parametric) or non-normal (non-parametric) distribution. Outliers 862 were excluded using the ROUT test. For each group, Mann-Whitney test or Kruskal-863 Wallis with Dunn's post-test was performed depending on the data distribution normal 864 or non-normal. The violin plot was chosen to demonstrate the statistical significance of 865 our analyses. Its format is directly proportional to the dispersion of the data, the dotted ⁸⁶⁶lines correspond to the minimum quartiles in the lower part and maximum in the upper 867 part, and the solid line represents the median. Data are represented by black dots (each 868 dot represents an individual) and were normalized in log10. In addition, all groups 869 received a specific color that represents them in all graphs and figures.

870

⁸⁷¹*Radar-Chart*

872 The radar chart is a graph that represents the frequency (in percentage) of high 873 producers of each plasma mediator represented and it has been previously described 17 . 874 On the charts, each axis represents the percentage (%) of volunteers showing high levels 875 of a specific mediator. The values of each axis can be connected to form a central 876 polygonal area that represents 50% of the baseline level and the external polygonal area 877 is equivalent to 100%. Increase or decrease of the central polygonal area reflects either 878 a higher or a lower contribution of the mediators for each group. We consider all 879 mediators that are above the internal polygonal area to be high producers.

880

⁸⁸¹*Network analysis*

⁸⁸²A weighted network analysis was used to investigate the correlations between 883 biologically relevant markers associated with cytokines and cellular proteins (listed in

⁸⁸⁴**Supplementary Table 5** and selected based on their potential relevance for the study). ⁸⁸⁵To quantify the relationships between these markers, we utilized Spearman Rank 886 correlation, a non-parametric method that ranks the data points for each variable and 887 calculates the correlation coefficient based on the ranks. This approach is suitable for ⁸⁸⁸data that may not follow a normal distribution or have outliers. The correlation 889 coefficient ranges from -1 to 1, where 1 indicates a perfect positive correlation, -1 890 indicates a perfect negative correlation, and 0 indicates no correlation. To focus on 891 significant correlations, we established a threshold of p-values less than 0.05. This 892 filtering step ensured that only statistically significant relationships were included in the 893 network analysis. The resulting network was visualized using a spring layout, a graph 894 drawing algorithm that positions nodes based on the forces of attraction and repulsion 895 between them. This layout is particularly effective for identifying clusters or modules 896 within the network, providing insights into the underlying structure of the relationships. 897 The strength of correlations was visually represented by the darker of the lines 898 connecting nodes. Darker lines indicated stronger relationships between variables, while 899 lighter lines suggested weaker associations. Additionally, the size of each node 900 corresponded to the number of correlations it participated in, providing a visual cue for 901 the variable's centrality within the network. Larger nodes represented variables with 902 more connections, highlighting their importance in the overall system. By visualizing 903 the network in this manner, we were able to gain insights into the interactions between 904 cytokines/chemokines and cellular proteins, identifying key players and potential 905 regulatory mechanisms within the biological system under study.

⁹⁰⁷**References**

908 1. Wu, Z. & McGoogan, J. M. Characteristics of and Important Lessons from the 909 Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a 910 Report of 72314 Cases from the Chinese Center for Disease Control and 911 Prevention. *JAMA - J. Am. Med. Assoc.* **323**, 1239–1242 (2020). ⁹¹²2. Grasselli, G. *et al.* Baseline Characteristics and Outcomes of 1591 Patients 913 Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. ⁹¹⁴*JAMA* **³²³**, 1574–1581 (2020). ⁹¹⁵3. Cerqueira-Silva, T. *et al.* Influence of age on the effectiveness and duration of

1071

¹⁰⁷²**Figure Legends:**

1073 **Figure 1: Early inflammatory profile of COVID-19 and Flu-Like syndrome patients. (a)**
1074 Radar chart with the frequency of high mediator producers among individuals infected with 1074 Radar chart with the frequency of high mediator producers among individuals infected with
1075 COVID-19 from Belo Horizonte and São Paulo (n=36), Mild COVID-19 (n=20), Moderate 1075 COVID-19 from Belo Horizonte and São Paulo (n=36), Mild COVID-19 (n=20), Moderate
1076 COVID-19 (n=6) and Severe COVID-19 (n=10). (b) Differences in plasma mediator 1076 COVID-19 ($n=6$) and Severe COVID-19 ($n=10$). (**b**) Differences in plasma mediator 1077 concentrations in individuals with different clinical forms of COVID-19. The population used 1077 concentrations in individuals with different clinical forms of COVID-19. The population used
1078 for this analysis was the same as that used in Figure 1A. Samples were previously normalized, 1078 for this analysis was the same as that used in Figure 1A. Samples were previously normalized,
1079 and outliers were excluded using the ROUT test. Mann-Whitney test was performed 1079 and outliers were excluded using the ROUT test. Mann-Whitney test was performed
1080 individually for each group. Lines were used to represent which groups were compared and 1080 individually for each group. Lines were used to represent which groups were compared and
1081 asterisks to represent statistical significance ($p \le 0.05$, ** $p \le 0.01$, *** $p \le 0.001$ or **** $p \le 0.0001$). 1081 asterisks to represent statistical significance (p≤0.05, **p≤0.01, ***p≤0.001 or ****p<0.0001).
1082 (c) Radar chart representing the frequency of high mediator producers among individuals 1082 (c) Radar chart representing the frequency of high mediator producers among individuals
1083 infected with COVID-19, using individuals from Belo Horizonte and São Paulo (n=74), Flu-1083 infected with COVID-19, using individuals from Belo Horizonte and São Paulo (n=74), Flu-
1084 Like Syndrome (n=38), Mild COVID-19 (n=42). (d) Comparative analysis of the concentration 1084 Like Syndrome (n=38), Mild COVID-19 (n=42). **(d)** Comparative analysis of the concentration
1085 of each mediator among groups. Samples were previously normalized, and outliers were 1085 of each mediator among groups. Samples were previously normalized, and outliers were
1086 excluded from the data, using the ROUT test. Mann-Whitney test was performed individually 1086 excluded from the data, using the ROUT test. Mann-Whitney test was performed individually
1087 for each group. Asterisks to represent statistical significance (p <0.05, ** p <0.01, ** p <0.001 or 1087 for each group. Asterisks to represent statistical significance ($p≤0.05$, ** $p≤0.01$, *** $p≤0.001$ or 1088 ****p<0.0001). (e) Radar charts representing the frequency of high producers of plasma 1088 ****p<0.0001). **(e)** Radar charts representing the frequency of high producers of plasma
1089 mediators in individuals from Belo Horizonte (n=46) with Flu-Like Syndrome (n=13), Mild 1089 mediators in individuals from Belo Horizonte (n=46) with Flu-Like Syndrome (n=13), Mild
1090 COVID-19 (n=14), Hospitalized COVID-19 (n=12) and COVID-19 Progression (n=7). The 1090 COVID-19 (n=14), Hospitalized COVID-19 (n=12) and COVID-19 Progression (n=7). The
1091 Hospitalized COVID-19 group consists of individuals who were hospitalized with either 1091 Hospitalized COVID-19 group consists of individuals who were hospitalized with either
1092 moderate or severe COVID-19. (f) Analysis of the concentration of plasma mediators of 1092 moderate or severe COVID-19. **(f)** Analysis of the concentration of plasma mediators of 1093 individuals from Belo Horizonte with either COVID-19 or Flu-Like Syndrome (FS). The 1093 individuals from Belo Horizonte with either COVID-19 or Flu-Like Syndrome (FS). The population used for this analysis was the same as that used in D. Asterisks represent statistical 1094 population used for this analysis was the same as that used in D. Asterisks represent statistical
1095 significance (*p \leq 0.05, **p0.001, ***p0.001 or ****p0.0001). All groups presented in this 1095 significance (*p≤0.05, **p0.001, ***p0.001 or ****p0.0001). All groups presented in this 1096 figure were matched by sex as well as age and they were composed of individuals at the initial 1096 figure were matched by sex as well as age and they were composed of individuals at the initial
1097 stage of infection (1-4 days of symptoms). stage of infection (1-4 days of symptoms).

1098

1099 Figure 2: Inflammatory profiles of adult and elderly people with Flu-like syndrome and 1100 COVID-19 living in endemic and in non-endemic areas for infectious diseases. (a) Radar ¹¹⁰⁰**COVID-19 living in endemic and in non-endemic areas for infectious diseases. (a)** Radar 1101 chart representing the frequency of high producers of mediators among individuals from
1102 Governador Valadares ($n=56$) with either Flu-Like Syndrome ($n=30$) or Mild COVID-19 1102 Governador Valadares (n=56) with either Flu-Like Syndrome (n=30) or Mild COVID-19
1103 (n=26). (b) Comparative analysis of concentrations of plasma mediators in individuals with 1103 (n=26). **(b)** Comparative analysis of concentrations of plasma mediators in individuals with
1104 either Flu-like syndrome or Mild COVID-19. Samples were previously normalized, and outliers 1104 either Flu-like syndrome or Mild COVID-19. Samples were previously normalized, and outliers
1105 were excluded using the ROUT test. Mann-Whitney test was performed individually for each were excluded using the ROUT test. Mann-Whitney test was performed individually for each 1106 group. Asterisks represent statistical significance ($p\leq 0.05$, **p ≤ 0.01 , ***p ≤ 0.001 or

^{****}p<0.0001). **(c)** Radar charts representing the frequency of high producers of mediators
1108 among individuals with COVID-19 in the adult (20-59 vears) and elderly (over 60 vears) age 1108 among individuals with COVID-19 in the adult (20-59 years) and elderly (over 60 years) age
1109 groups in a non-endemic area (Belo Horizonte and São Paulo) - Adults (n=92) with Flu-Like 1109 groups in a non-endemic area (Belo Horizonte and São Paulo) - Adults (n=92) with Flu-Like
1110 Syndrome (n=45) and Mild COVID-19 (n=47) and elderly (n=19) with Flu-Like Syndrome 1110 Syndrome (n=45) and Mild COVID-19 (n=47) and elderly (n=19) with Flu-Like Syndrome
1111 (n=11) or Mild COVID-19 (n=8) and in an endemic area (Governador Valadares) - Adults 1111 (n=11) or Mild COVID-19 (n=8) and in an endemic area (Governador Valadares) - Adults
1112 (n=75) with Flu-Like Syndrome (n=39) and Mild COVID-19 (n=36) and elderly (n=11) with 1112 (n=75) with Flu-Like Syndrome (n=39) and Mild COVID-19 (n=36) and elderly (n=11) with
1113 Flu-Like Syndrome (n=5) and Mild COVID-19 (n=6) (d) Radar charts representing the 1113 Flu-Like Syndrome (n=5) and Mild COVID-19 (n=6) **(d)** Radar charts representing the 1114 frequency of high producers of CXCL9 among all individuals with Flu-Like Syndrome and 1114 frequency of high producers of CXCL9 among all individuals with Flu-Like Syndrome and
1115 COVID-19 in the adult and elderly age groups - (Adults n=40) with FS (n=14), Mild COVID-19 1115 COVID-19 in the adult and elderly age groups - (Adults n=40) with FS (n=14), Mild COVID-19
1116 (n=15) and Hospitalized (n=11), elderly (n=26) with FLS (n=13), Mild COVID-19 (n=7) and 1116 (n=15) and Hospitalized (n=11), elderly (n=26) with FLS (n=13), Mild COVID-19 (n=7) and
1117 Hospitalized (n=6), (e) Comparative analysis of plasma concentrations of CXCL-9 in 1117 Hospitalized (n=6). **(e)** Comparative analysis of plasma concentrations of CXCL-9 in 1118 individuals with different clinical forms of COVID-19. Samples were previously normalized, 1118 individuals with different clinical forms of COVID-19. Samples were previously normalized,
1119 and outliers were excluded using the ROUT test. Mann-Whitney test was performed 1119 and outliers were excluded using the ROUT test. Mann-Whitney test was performed 1120 individually for each group. Asterisks represent statistical significance ($p \le 0.05$, $\frac{10000 \text{ m/s}}{10000 \text{ m}}$) 1120 individually for each group. Asterisks represent statistical significance ($p≤0.05$, ** $p≤0.01$, 1121 *** $p≤0.001$ or **** $p≤0.0001$). (f) Comparative analysis of plasma concentrations of CXCL-9 1121 ***p≤0.001 or ****p<0.0001). **(f)** Comparative analysis of plasma concentrations of CXCL-9
1122 in individuals with different clinical forms of COVID-19. The population used is the same 1122 in individuals with different clinical forms of COVID-19. The population used is the same
1123 shown in Figure 2C. Samples were previously normalized, and outliers were excluded from the 1123 shown in Figure 2C. Samples were previously normalized, and outliers were excluded from the
1124 data using the ROUT test. Thus, the Mann-Whitney test was performed individually for each 1124 data using the ROUT test. Thus, the Mann-Whitney test was performed individually for each
1125 group. Lines were used to represent which groups were compared and asterisks to represent 1125 group. Lines were used to represent which groups were compared and asterisks to represent 1126 statistical significance $(p<0.05, **p<0.01, **p<0.001$ or $****p<0.0001$). All groups presented 1126 statistical significance (p≤0.05, **p≤0.01, ***p≤0.001 or ****p<0.0001). All groups presented
1127 in this figure were matched by sex as well as age and they were composed of individuals at the 1127 in this figure were matched by sex as well as age and they were composed of individuals at the 1128 initial stage of infection (1-4 days of symptoms). initial stage of infection $(1-4 \text{ days of symptoms}).$

1129

1130 Figure 3: The senescence and exhaustion profile was significantly increased in individuals
1131 with moderate or severe COVID-19 compared to mild individuals in both CD8⁺ and CD4⁺ 1131 with moderate or severe COVID-19 compared to mild individuals in both CD8⁺ and CD4⁺ 1132 **T cells.** Patients were also stratified into 3 groups classified according to the severity of the 1133 disease as mild $(n=20)$, moderate $(n=8)$ and severe $(n=8)$. (a) Percentage of senescent and 1133 disease as mild $(n=20)$, moderate $(n=8)$ and severe $(n=8)$. (**a**) Percentage of senescent and 1134 exhausted CD8⁺ T cells from individuals with mild, moderate and severe COVID. (**b**) The exhausted CD8⁺ T cells from individuals with mild, moderate and severe COVID. (**b**) The gating strategy was used to analyze markers related to senescence and exhaustion together 1135 gating strategy was used to analyze markers related to senescence and exhaustion together
1136 within $CD8^+$ T cells. Senescence cells are TIGIT⁺; exhausted are PD-1⁺ and ICOS⁺. (c) 1136 within $CD8^+$ T cells. Senescence cells are TIGIT⁺; exhausted are PD-1⁺ and ICOS⁺. (c) Percentage of senescent/exhausted $CD8^+$ T cells from individuals with mild (20), moderate (8)
1138 and severe (8) COVID-19. Senescent/exhausted $CD8^+$ T cells quantified by co-expression of and severe (8) COVID-19. Senescent/exhausted $CD8^+$ T cells quantified by co-expression of 1139 co- $CD57^+$ and $PD-1^+$, $CD28$ neg and $PD-1^+$, $TIGIT^+$ and $ICOS^+$. KLRG1⁺ marker may be present in 1139 $CD57^+$ and PD-1⁺, CD28neg and PD-1⁺, TIGIT⁺ and ICOS⁺. KLRG1⁺ marker may be present in senescent and exhausted. (**d**) Representative flow cytometry of senescent/exhausted CD8⁺ T
1141 cells, with the gate of interest showing a red square. (**e**) Percentage of senescent and exhausted 1141 cells, with the gate of interest showing a red square. (**e**) Percentage of senescent and exhausted
1142 CD4⁺T cells from individuals with mild, moderate and severe COVID. (**f**) Dot plots of $CD4^+$ T cells from individuals with mild, moderate and severe COVID. (**f**)

1143 strategy was used to analyze markers related to senescence TIGIT⁺, CD57⁺, CD28neg and 1144 KLRG1⁺, to exhaustion marker $ICOS⁺$ and $KLRG1⁺$ within $CD4⁺$ T cells was used (red square). 1145 $*p < 0.05, **p < 0.01$.

¹¹⁴⁶**Figure 4: Analysis of immunoglobulin repertoires and of biological aging in patients with** 1147 **different clinical forms of COVID-19.** (a) Graphical representation of clonal expansion of the 1148 100 most expanded clones in the repertoire of five individuals. The more intense the color, the 1148 100 most expanded clones in the repertoire of five individuals. The more intense the color, the more expanded the clone is. (b) Shannon entropy diversity was calculated using the diversity 1149 more expanded the clone is. **(b)** Shannon entropy diversity was calculated using the diversity
1150 function of the 'vegan' package with the 100 most expanded clones for hospitalized individuals 1150 function of the 'vegan' package with the 100 most expanded clones for hospitalized individuals $(n=20, Red)$, individuals with mild cases $(N=19, Yellow)$, and negative individuals $(n=6, Blue-$ 1151 (n=20, Red), individuals with mild cases (N=19, Yellow), and negative individuals (n=6, Blue-
1152 Cyan) from Belo Horizonte and Governador Valadares (only mild cases). Differences among 1152 Cyan) from Belo Horizonte and Governador Valadares (only mild cases). Differences among
1153 groups were calculated using Mann-Whitney test and ROUT test to exclude outliers. Asteriscs 1153 groups were calculated using Mann-Whitney test and ROUT test to exclude outliers. Asteriscs
1154 represent statistical significance (*p<0.01). (c) Repertoire maturity (divergence from germline-1154 represent statistical significance (*p<0.01). (**c**) Repertoire maturity (divergence from germline-
1155 like sequences) was calculated for the whole repertoire of hospitalized individuals (n=20, Red), 1155 like sequences) was calculated for the whole repertoire of hospitalized individuals (n=20, Red),
1156 individuals with mild cases (N=19, Yellow), and negative individuals (n=6, Blue-Cyan) from 1156 individuals with mild cases (N=19, Yellow), and negative individuals (n=6, Blue-Cyan) from
1157 Belo Horizonte and Governador Valadares (only mild cases). The ROUTE test was performed 1157 Belo Horizonte and Governador Valadares (only mild cases). The ROUTE test was performed
1158 to remove outliers. (d) Accelerated aging was measured using eight different epigenetic clocks 1158 to remove outliers. **(d)** Accelerated aging was measured using eight different epigenetic clocks
1159 (Horvath; New Horvath; Levine; Hannum; BLUP; EN; Wu; TL) in unvaccinated COVID-19 1159 (Horvath; New Horvath; Levine; Hannum; BLUP; EN; Wu; TL) in unvaccinated COVID-19
1160 negative control individuals $(n = 12)$ (Blue-Cyan), infected with COVID-19 Mild 9 $(n = 9)$ 1160 negative control individuals (n = 12) (Blue-Cyan), infected with COVID-19 Mild 9 (n = 9)
1161 (Yellow) and infected with Hospitalized COVID-19 (n = 17) (Red) without including endemic 1161 (Yellow) and infected with Hospitalized COVID-19 ($n = 17$) (Red) without including endemic
1162 area. The v-axis shows the acceleration of epigenetic age after adjustment for cell type fractions 1162 area. The y-axis shows the acceleration of epigenetic age after adjustment for cell type fractions
1163 (Residual Regression of Epigenetic Age Acceleration on Cell Type Fractions). The box plot 1163 (Residual Regression of Epigenetic Age Acceleration on Cell Type Fractions). The box plot
1164 represents the median, interquartile, minimum and maximum values of age acceleration (in 1164 represents the median, interquartile, minimum and maximum values of age acceleration (in 1165 vears) determined for each group. One-way ANOVA and t-test were used to evaluate significant 1165 years) determined for each group. One-way ANOVA and t-test were used to evaluate significant 1166 differences. Values of $p < 0.05$ were considered statistically significant (*). (e) The same 1166 differences. Values of $p < 0.05$ were considered statistically significant (*). **(e)** The same 1167 analysis as in Figure 4D was performed but including individuals from endemic areas. The 1167 analysis as in Figure 4D was performed but including individuals from endemic areas. The population used includes unvaccinated COVID-19 negative control individuals $(n = 12)$ (Blue-1168 population used includes unvaccinated COVID-19 negative control individuals (n = 12) (Blue-
1169 Cyan), infected with COVID-19 Mild 9 (n = 18) (Yellow) and infected with COVID-19 1169 Cyan), infected with COVID-19 Mild 9 (n = 18) (Yellow) and infected with COVID-19
1170 Hospitalized (n = 18) (Red). (f) Biological network of cytokines and cellular proteins of 1170 Hospitalized (n = 18) (Red). **(f)** Biological network of cytokines and cellular proteins of 1171 exhaustion and senescence in infected individuals with mild and severe COVID-19. Patients 1171 exhaustion and senescence in infected individuals with mild and severe COVID-19. Patients
1172 who developed severe COVID-19 showed greater interactions with biomarkers of senescence 1172 who developed severe COVID-19 showed greater interactions with biomarkers of senescence
1173 and exhaustion in immune cells (including cytokines, chemokines, and cell surface markers) up 1173 and exhaustion in immune cells (including cytokines, chemokines, and cell surface markers) up
1174 to 4 days after infection, when compared to patients who developed the mild form of the 1174 to 4 days after infection, when compared to patients who developed the mild form of the
1175 disease. Blue thicker lines indicate positive correlations and red thicker lines negative 1175 disease. Blue thicker lines indicate positive correlations and red thicker lines negative
1176 correlations. The description of the codes present in the graph is in Supplementary Table 5. The 1176 correlations. The description of the codes present in the graph is in Supplementary Table 5. The 1177 size of the circles is proportional to their importance as hubs of connection. (**g**) A graphical 1177 size of the circles is proportional to their importance as hubs of connection. **(g)** A graphical
1178 representation of the main biomarkers of aging (cytokines/chemokines, Ig repertoire, DNA representation of the main biomarkers of aging (cytokines/chemokines, Ig repertoire, DNA

-
- 1179 methylation, cellular markers of exhaustion and senescence) illustrates the comparative
1180 differences between individuals with Mild and Severe COVID-19 comparing them with the
- 1180 differences between individuals with Mild and Severe COVID-19 comparing them with the
1181 same markers described for aged individuals. The size of the circles is proportional to the 1181 same markers described for aged individuals. The size of the circles is proportional to the 1182 intensity of the parameter they represent.
- intensity of the parameter they represent.

¹¹⁸³**Tables**

¹¹⁸⁴**Table 1: Characterization of the study sample**

1185
1186 1186 Data presented as median (min-max) and mean $(\pm$ standard deviation). The Kruskal-Wallis and 1187 Dunn's tests were applied. *Corresponds to the difference found for comparison between the

1187 Dunn's tests were applied. *Corresponds to the difference found for comparison between the 1188 other compared groups.

other compared groups.

1191

¹¹⁹²**Table 2: Characterization of the study sample by region**

1193

1194 Data presented as median (min-max) and mean $(\pm$ standard deviation). The Kruskal-Wallis and
1195 Dunn's tests were applied. *Corresponds to the difference found for comparison between the

1195 Dunn's tests were applied. *Corresponds to the difference found for comparison between the 1196 other compared groups.

other compared groups.

1197

 $\mathbf d$

